OBJECTIVE: Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200 mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at the lumbar spine. DESIGN: Comparative double-blind randomized multicenter study in parallel groups. SETTING:200 patients of both genders of at least 50 years old with joint pain assessed as ≥30 mm on a visual analogical scale (VAS). INTERVENTION: Collagen hydrolysate 1200 mg/day or placebo during 6 months. MAIN OUTCOME MEASURE: Comparison of the percentage of clinical responder between the active collagen hydrolysate group and the placebo group after 6 months of study. A responder subject was defined as a subject experiencing a clinically significant improvement (i.e. by 20% or more) in the most painful joint using the VAS score. All analyses were performed using an intent-to-treat procedure. RESULTS: At 6 months, the proportion of clinical responders to the treatment, according to VAS scores, was significantly higher in the collagen hydrolysate (CH) group 51.6%, compared to the placebo group 36.5% (p<0.05). However, there was no significant difference between groups at 3 months (44.1% vs. 39.6%, p=0.53). No significant difference in terms of security and tolerability was observed between the two groups. CONCLUSIONS: This study suggests that collagen hydrolysate 1200 mg/day could increase the number of clinical responders (i.e. improvement of at least 20% on the VAS) compared to placebo. More studies are needed to confirm the clinical interest of this food supplement.
RCT Entities:
OBJECTIVE: Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200 mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at the lumbar spine. DESIGN: Comparative double-blind randomized multicenter study in parallel groups. SETTING: 200 patients of both genders of at least 50 years old with joint pain assessed as ≥30 mm on a visual analogical scale (VAS). INTERVENTION: Collagen hydrolysate 1200 mg/day or placebo during 6 months. MAIN OUTCOME MEASURE: Comparison of the percentage of clinical responder between the active collagen hydrolysate group and the placebo group after 6 months of study. A responder subject was defined as a subject experiencing a clinically significant improvement (i.e. by 20% or more) in the most painful joint using the VAS score. All analyses were performed using an intent-to-treat procedure. RESULTS: At 6 months, the proportion of clinical responders to the treatment, according to VAS scores, was significantly higher in the collagen hydrolysate (CH) group 51.6%, compared to the placebo group 36.5% (p<0.05). However, there was no significant difference between groups at 3 months (44.1% vs. 39.6%, p=0.53). No significant difference in terms of security and tolerability was observed between the two groups. CONCLUSIONS: This study suggests that collagen hydrolysate 1200 mg/day could increase the number of clinical responders (i.e. improvement of at least 20% on the VAS) compared to placebo. More studies are needed to confirm the clinical interest of this food supplement.
Authors: Bastien Bourdon; Frédéric Cassé; Nicolas Gruchy; Pierre Cambier; Sylvain Leclercq; Sarah Oddoux; Antoine Noël; Jérôme E Lafont; Romain Contentin; Philippe Galéra Journal: Int J Mol Sci Date: 2021-04-01 Impact factor: 5.923
Authors: E van de Water; M Oosterlinck; M Dumoulin; N M Korthagen; P R van Weeren; J van den Broek; H Everts; F Pille; D A van Doorn Journal: Equine Vet J Date: 2016-10-13 Impact factor: 2.888